Search details
1.
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.
Cell
; 183(2): 347-362.e24, 2020 10 15.
Article
in English
| MEDLINE | ID: mdl-33064988
2.
Therapy-induced APOBEC3A drives evolution of persistent cancer cells.
Nature
; 620(7973): 393-401, 2023 Aug.
Article
in English
| MEDLINE | ID: mdl-37407818
3.
Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
N Engl J Med
; 390(2): 118-131, 2024 Jan 11.
Article
in English
| MEDLINE | ID: mdl-38197815
4.
Pralsetinib in patients with RET fusion-positive non-small-cell lung cancer: A plain language summary of the ARROW study.
Future Oncol
; 20(6): 297-306, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-37916501
5.
NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types.
Br J Cancer
; 126(3): 514-520, 2022 02.
Article
in English
| MEDLINE | ID: mdl-34480094
6.
An early look at selective RET inhibitor resistance: new challenges and opportunities.
Br J Cancer
; 124(11): 1757-1758, 2021 05.
Article
in English
| MEDLINE | ID: mdl-33758332
7.
Imaging Features and Metastatic Patterns of Advanced ALK-Rearranged Non-Small Cell Lung Cancer.
AJR Am J Roentgenol
; 214(4): 766-774, 2020 04.
Article
in English
| MEDLINE | ID: mdl-31887093
8.
Time to tackle the blood-brain barrier in HER2-mutant lung cancer.
Cancer
; 125(24): 4363-4366, 2019 12 15.
Article
in English
| MEDLINE | ID: mdl-31469415
9.
ATLANTIC: a sea change in immunotherapy for oncogene-driven lung cancer?
Lancet Oncol
; 19(4): 438-439, 2018 04.
Article
in English
| MEDLINE | ID: mdl-29545096
10.
Unlocking the Next Frontier in Precision Oncology: Addressing Drug-Tolerant Residual Disease.
Cancer Discov
; 14(6): 915-919, 2024 Jun 03.
Article
in English
| MEDLINE | ID: mdl-38826097
11.
Efficacy and Safety of Dose-Escalated Alectinib in Patients With Metastatic ALK-Positive NSCLC and Central Nervous System Relapse on Standard-Dose Alectinib.
JTO Clin Res Rep
; 5(3): 100645, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-38425547
12.
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study.
J Thorac Oncol
; 2024 Jan 24.
Article
in English
| MEDLINE | ID: mdl-38278303
13.
Raising the bar on first-line immunotherapy in lung cancer.
Lancet Oncol
; 18(1): 2-3, 2017 01.
Article
in English
| MEDLINE | ID: mdl-27932066
14.
ALK-positive lung cancer: a moving target.
Nat Cancer
; 4(3): 330-343, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36797503
15.
Real-World Comparative Effectiveness of First-Line Alectinib Versus Crizotinib in Patients With Advanced ALK-Positive NSCLC With or Without Baseline Central Nervous System Metastases.
JTO Clin Res Rep
; 4(4): 100483, 2023 Apr.
Article
in English
| MEDLINE | ID: mdl-37025119
16.
Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis.
JTO Clin Res Rep
; 4(8): 100534, 2023 Aug.
Article
in English
| MEDLINE | ID: mdl-37533439
17.
Factors Associated With Developing Neurocognitive Adverse Events in Patients Receiving Lorlatinib After Progression on Other Targeted Therapies.
J Thorac Oncol
; 18(1): 67-78, 2023 01.
Article
in English
| MEDLINE | ID: mdl-36184067
18.
Lorlatinib and capmatinib in a ROS1-rearranged NSCLC with MET-driven resistance: tumor response and evolution.
NPJ Precis Oncol
; 7(1): 116, 2023 Nov 03.
Article
in English
| MEDLINE | ID: mdl-37923925
19.
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations.
Cancer Discov
; 13(3): 598-615, 2023 03 01.
Article
in English
| MEDLINE | ID: mdl-36511802
20.
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC.
J Thorac Oncol
; 18(6): 731-743, 2023 06.
Article
in English
| MEDLINE | ID: mdl-36775193